GT199900044A
(es)
*
|
1998-04-10 |
2000-09-14 |
|
Procedimientos para preparar haluros de fenoxifenilsulfonilo.
|
PA8469601A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Procedimiento para alquilar sulfonamidas impedidas estericamente
|
PT952148E
(pt)
*
|
1998-04-10 |
2004-09-30 |
Pfizer Prod Inc |
Derivados de acido ciclobutil-ariloxiarilsulfonilamino-hidroxamico
|
PA8469301A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Procedimientos para la preparacion de acidos hidroxamicos.
|
WO2000058278A1
(en)
*
|
1999-03-26 |
2000-10-05 |
Shionogi & Co., Ltd. |
β-AMINO ACID DERIVATIVES
|
AU3196300A
(en)
*
|
1999-03-26 |
2000-10-16 |
Shionogi & Co., Ltd. |
Carbocyclic sulfonamide derivatives
|
EP1041072B1
(en)
*
|
1999-03-31 |
2003-07-16 |
Pfizer Products Inc. |
Dioxocyclopentyl hydroxamic acids
|
ATE260251T1
(de)
|
1999-08-18 |
2004-03-15 |
Warner Lambert Co |
Hydroxamsäurederivate als matrix- metalloproteinase-inhibitoren
|
IL138686A0
(en)
*
|
1999-10-01 |
2001-10-31 |
Pfizer Prod Inc |
α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
|
AP2072A
(en)
|
2001-01-05 |
2009-12-10 |
Pfizer |
Antibodies to insulin-like growth factor I receptor
|
ATE467629T1
(de)
*
|
2001-03-14 |
2010-05-15 |
Novartis Pharma Gmbh |
Azacycloalkyl-substituierte essigsäure-derivate zur verwendung als mmp-inhibitoren
|
US6995171B2
(en)
|
2001-06-21 |
2006-02-07 |
Agouron Pharmaceuticals, Inc. |
Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
|
CA2471814C
(en)
|
2001-12-27 |
2011-03-15 |
Sumitomo Pharmaceuticals Co., Ltd. |
Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
|
EA008501B1
(ru)
|
2002-12-19 |
2007-06-29 |
Пфайзер Инк. |
2-(1н-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
GB0326546D0
(en)
*
|
2003-11-14 |
2003-12-17 |
Amersham Plc |
Inhibitor imaging agents
|
JP4869075B2
(ja)
|
2003-11-19 |
2012-02-01 |
アレイ バイオファーマ、インコーポレイテッド |
Mekの複素環阻害剤及びその使用方法
|
WO2006004429A2
(en)
*
|
2004-07-02 |
2006-01-12 |
Ge Healthcare As |
Imaging agents comprising a non- peptidic vector linked to a fluorophore via a polyethylene glycol linker
|
AU2005276135B2
(en)
*
|
2004-08-26 |
2011-04-28 |
Pfizer Inc. |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
CN102942522A
(zh)
|
2005-05-18 |
2013-02-27 |
阵列生物制药公司 |
Mek的杂环抑制剂及其使用方法
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
EP1926996B1
(en)
|
2005-09-20 |
2011-11-09 |
OSI Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2007121269A2
(en)
|
2006-04-11 |
2007-10-25 |
Ardea Biosciences, Inc. |
N-aryl-n'alkyl sulfamides as mek inhibitors
|
WO2007121481A2
(en)
|
2006-04-18 |
2007-10-25 |
Ardea Biosciences, Inc. |
Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
|
JP5491199B2
(ja)
|
2007-01-19 |
2014-05-14 |
アルデア バイオサイエンシズ,インコーポレイティド |
Mekのインヒビター
|
ES2593486T3
(es)
|
2007-04-18 |
2016-12-09 |
Pfizer Products Inc. |
Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
PT2690101E
(pt)
|
2007-12-19 |
2015-10-08 |
Genentech Inc |
5-anilinoimidazopiridinas e métodos de utilização
|
JP5710269B2
(ja)
|
2007-12-21 |
2015-04-30 |
ジェネンテック, インコーポレイテッド |
アザインドリジン類と使用方法
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
ES2586032T3
(es)
|
2008-03-28 |
2016-10-11 |
Hale Biopharma Ventures, Llc |
Administración de composiciones de benzodiazepinas
|
IL295601B2
(en)
|
2009-02-05 |
2024-11-01 |
Immunogen Inc |
History of benzodiazepines and processes for their preparation
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401613A2
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US20120128670A1
(en)
|
2009-07-31 |
2012-05-24 |
OSI Pharmaceuticals, LLC |
mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
|
KR20120094165A
(ko)
|
2009-10-13 |
2012-08-23 |
알로스팀 테라퓨틱스 엘엘씨 |
질병의 치료에 유용한 신규 mek 억제제
|
EP2496567B1
(en)
|
2009-11-05 |
2017-07-12 |
Rhizen Pharmaceuticals S.A. |
Novel benzopyran kinase modulators
|
TW201141536A
(en)
*
|
2009-12-21 |
2011-12-01 |
Colgate Palmolive Co |
Oral care compositions and methods
|
EP2533810B1
(en)
|
2010-02-10 |
2016-10-12 |
ImmunoGen, Inc. |
Cd20 antibodies and uses thereof
|
PT3150610T
(pt)
|
2010-02-12 |
2019-11-11 |
Pfizer |
Sais e polrmorfos de 8-fluor0-2-{4- [(metilamino}metil]fenil}-1,3,4,5-tetrahidr0-6hazepin0[ 5,4,3-cd]indol-6-0na
|
AU2011223643A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
CA2783665A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
CA2802857C
(en)
|
2010-06-16 |
2018-09-11 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Antibodies to endoplasmin and their use
|
BR112013017670B1
(pt)
|
2011-01-10 |
2022-07-19 |
Infinity Pharmaceuticals, Inc |
Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas
|
ES2717657T3
(es)
|
2011-02-15 |
2019-06-24 |
Immunogen Inc |
Métodos para la preparación de conjugados
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
DK3415139T3
(da)
|
2011-06-14 |
2022-06-20 |
Neurelis Inc |
Administration af benzodiazepin
|
JP6105578B2
(ja)
|
2011-07-21 |
2017-03-29 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
複素環式プロテインキナーゼ阻害剤
|
WO2013049332A1
(en)
|
2011-09-29 |
2013-04-04 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
US9452215B2
(en)
|
2012-02-22 |
2016-09-27 |
The Regents Of The University Of Colorado |
Bourvadin derivatives and therapeutic uses thereof
|
EP2817004B1
(en)
|
2012-02-22 |
2018-04-11 |
The Regents of The University of Colorado, A Body Corporate |
Bouvardin derivatives and therapeutic uses thereof
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
DK2859017T3
(da)
|
2012-06-08 |
2019-05-13 |
Sutro Biopharma Inc |
Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
|
ES2611788T3
(es)
|
2012-06-26 |
2017-05-10 |
Sutro Biopharma, Inc. |
Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
|
EP2887965A1
(en)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Cytotoxic benzodiazepine derivatives
|
KR102182800B1
(ko)
|
2012-08-31 |
2020-11-25 |
서트로 바이오파마, 인크. |
아지도 기를 포함하는 변형된 아미노산
|
JP6243918B2
(ja)
|
2012-10-16 |
2017-12-06 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
Pkm2調節因子およびそれらの使用方法
|
US9901647B2
(en)
|
2013-02-28 |
2018-02-27 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
WO2014134483A2
(en)
|
2013-02-28 |
2014-09-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
MX2015012062A
(es)
|
2013-03-14 |
2016-05-05 |
Tolero Pharmaceuticals Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
WO2014143659A1
(en)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the gtpase k-ras g12c
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
JP2017528498A
(ja)
|
2014-09-25 |
2017-09-28 |
アラクセス ファーマ エルエルシー |
Kras g12c変異体タンパク質のインヒビター
|
JP6621477B2
(ja)
|
2014-12-18 |
2019-12-18 |
ファイザー・インク |
ピリミジンおよびトリアジン誘導体ならびにaxl阻害薬としてのそれらの使用
|
US10246424B2
(en)
|
2015-04-10 |
2019-04-02 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
CN107995863A
(zh)
|
2015-04-20 |
2018-05-04 |
特雷罗药物股份有限公司 |
通过线粒体分析预测对阿伏西地的应答
|
ES2921350T3
(es)
|
2015-05-18 |
2022-08-24 |
Sumitomo Pharma Oncology Inc |
Profármacos de alvocidib que tienen biodisponibilidad aumentada
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
KR20180034538A
(ko)
|
2015-08-03 |
2018-04-04 |
톨레로 파마수티컬스, 인크. |
암의 치료를 위한 병행 요법
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
US10414757B2
(en)
|
2015-11-16 |
2019-09-17 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
JP6877429B2
(ja)
|
2015-12-03 |
2021-05-26 |
アジオス ファーマシューティカルズ, インコーポレイテッド |
Mtapヌル癌を処置するためのmat2a阻害剤
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
JP7306827B2
(ja)
|
2016-01-27 |
2023-07-11 |
ストロ バイオファーマ インコーポレーテッド |
抗cd74抗体コンジュゲート、抗cd74抗体コンジュゲートを含む組成物および抗cd74抗体コンジュゲートを使用する方法
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
AU2017263574B2
(en)
|
2016-05-12 |
2022-11-17 |
The Regents Of The University Of Michigan |
ASH1L inhibitors and methods of treatment therewith
|
US11118233B2
(en)
|
2016-05-18 |
2021-09-14 |
The University Of Chicago |
BTK mutation and ibrutinib resistance
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
AU2017321973B2
(en)
|
2016-09-02 |
2024-09-05 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2018068017A1
(en)
|
2016-10-07 |
2018-04-12 |
Araxes Pharma Llc |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
KR20190099260A
(ko)
|
2016-12-19 |
2019-08-26 |
톨레로 파마수티컬스, 인크. |
프로파일링 펩티드 및 감도 프로파일링을 위한 방법
|
CN116606261A
(zh)
|
2016-12-22 |
2023-08-18 |
美国安进公司 |
Kras g12c抑制剂及其使用方法
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
JP7117311B2
(ja)
|
2017-01-26 |
2022-08-12 |
ゼットリップ ホールディング リミテッド |
Cd47抗原結合単位およびその使用
|
EP3573964A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
|
US11944627B2
(en)
|
2017-03-24 |
2024-04-02 |
Kura Oncology, Inc. |
Methods for treating hematological malignancies and Ewing's sarcoma
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
US10736897B2
(en)
|
2017-05-25 |
2020-08-11 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
WO2018218070A2
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Covalent inhibitors of kras
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
WO2019023316A1
(en)
|
2017-07-26 |
2019-01-31 |
Sutro Biopharma, Inc. |
METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
|
AU2018329920B2
(en)
|
2017-09-08 |
2022-12-01 |
Amgen Inc. |
Inhibitors of KRAS G12C and methods of using the same
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
US12071477B2
(en)
|
2017-09-18 |
2024-08-27 |
Sutro Biopharma, Inc. |
Anti-folate receptor alpha antibody conjugated with hemiasterlins
|
TW201920170A
(zh)
|
2017-09-20 |
2019-06-01 |
美商庫拉腫瘤技術股份有限公司 |
經取代之menin-mll 抑制劑及使用方法
|
EP3706737A4
(en)
|
2017-11-10 |
2021-10-20 |
The Regents of the University of Michigan |
ASH11 INHIBITORS AND METHOD OF TREATING THEREOF
|
CN112533602A
(zh)
|
2018-04-05 |
2021-03-19 |
大日本住友制药肿瘤公司 |
Axl激酶抑制剂及其用途
|
MA52496A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
JP7266043B2
(ja)
|
2018-05-04 |
2023-04-27 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
AU2019265822B2
(en)
|
2018-05-10 |
2024-07-18 |
Amgen Inc. |
KRAS G12C inhibitors for the treatment of cancer
|
MA52765A
(fr)
|
2018-06-01 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
CA3102777A1
(en)
|
2018-06-07 |
2019-12-12 |
The Regents Of The University Of Michigan |
Prc1 inhibitors and methods of treatment therewith
|
WO2019241157A1
(en)
|
2018-06-11 |
2019-12-19 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
EP3807276A2
(en)
|
2018-06-12 |
2021-04-21 |
Amgen Inc. |
Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
CN112512597A
(zh)
|
2018-07-26 |
2021-03-16 |
大日本住友制药肿瘤公司 |
用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
|
KR20210045998A
(ko)
|
2018-08-01 |
2021-04-27 |
아락세스 파마 엘엘씨 |
헤테로사이클릭 스피로 화합물 및 암 치료를 위한 그의 사용 방법
|
EP3852811A1
(en)
|
2018-09-17 |
2021-07-28 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
JP7454572B2
(ja)
|
2018-11-19 |
2024-03-22 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤及びその使用方法
|
WO2020117988A1
(en)
|
2018-12-04 |
2020-06-11 |
Tolero Pharmaceuticals, Inc. |
Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
AU2019403486A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
KIF18A inhibitors
|
AU2019403488A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
KIF18A inhibitors
|
AU2019404576A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
JP2022513971A
(ja)
|
2018-12-20 |
2022-02-09 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
CN113767100A
(zh)
|
2019-03-01 |
2021-12-07 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
WO2020180770A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
JP7547360B2
(ja)
|
2019-03-22 |
2024-09-09 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Pkm2モジュレーターを含む組成物およびそれを使用する処置の方法
|
EP3962951A1
(en)
|
2019-05-03 |
2022-03-09 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
MX2021014126A
(es)
|
2019-05-21 |
2022-01-04 |
Amgen Inc |
Formas en estado solido.
|
WO2021003417A1
(en)
|
2019-07-03 |
2021-01-07 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
CA3146693A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
AU2020324963A1
(en)
|
2019-08-02 |
2022-02-24 |
Amgen Inc. |
KIF18A inhibitors
|
US20220372018A1
(en)
|
2019-08-02 |
2022-11-24 |
Amgen Inc. |
Kif18a inhibitors
|
WO2021055728A1
(en)
|
2019-09-18 |
2021-03-25 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
US20240190862A1
(en)
|
2019-10-24 |
2024-06-13 |
Amgen Inc. |
Epoxyamides as kras g12c and kras g12d inhibitors and methods of using the same
|
BR112022007783A8
(pt)
|
2019-10-28 |
2023-04-11 |
Merck Sharp & Dohme |
Composto, composição farmacêutica, e, métodos para inibir proteína g12c de kras e para tratar câncer
|
US20230023023A1
(en)
|
2019-10-31 |
2023-01-26 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
TW202132315A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras 抑制劑
|
AU2020377925A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
US11566007B2
(en)
|
2019-11-04 |
2023-01-31 |
Revolution Medicines, Inc. |
Ras inhibitors
|
MX2022005525A
(es)
|
2019-11-08 |
2022-06-08 |
Revolution Medicines Inc |
Compuestos de heteroarilo bicíclicos y usos de estos.
|
AU2020383535A1
(en)
|
2019-11-14 |
2022-05-05 |
Amgen Inc. |
Improved synthesis of KRAS G12C inhibitor compound
|
TW202132296A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Kras g12c抑制劑化合物之改善的合成
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
EP4087611A1
(en)
|
2020-01-07 |
2022-11-16 |
Revolution Medicines, Inc. |
Shp2 inhibitor dosing and methods of treating cancer
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
EP4139299A1
(en)
|
2020-04-24 |
2023-03-01 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
US20230181536A1
(en)
|
2020-04-24 |
2023-06-15 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
CA3183032A1
(en)
|
2020-06-18 |
2021-12-23 |
Mallika Singh |
Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
|
CA3185209A1
(en)
|
2020-07-10 |
2021-01-27 |
Alyssa WINKLER |
Gas41 inhibitors and methods of use thereof
|
US20230255972A1
(en)
|
2020-07-15 |
2023-08-17 |
Taiho Pharmaceutical Co., Ltd. |
Pyrimidine compound-containing combination to be used in tumor treatment
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
IL301298A
(en)
|
2020-09-15 |
2023-05-01 |
Revolution Medicines Inc |
Indole derivatives as RAS inhibitors in cancer therapy
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
US20240051956A1
(en)
|
2020-12-22 |
2024-02-15 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
MX2023012060A
(es)
|
2021-04-13 |
2024-01-22 |
Nuvalent Inc |
Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr.
|
TW202308702A
(zh)
|
2021-04-30 |
2023-03-01 |
美商西建公司 |
使用抗BCMA抗體藥物結合物(ADC)組合γ分泌酶抑制劑(GSI)之組合療法
|
TW202309052A
(zh)
|
2021-05-05 |
2023-03-01 |
美商銳新醫藥公司 |
Ras抑制劑
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ras阻害剤及びその使用
|
CN117616031A
(zh)
|
2021-05-05 |
2024-02-27 |
锐新医药公司 |
用于治疗癌症的ras抑制剂
|
US20240317759A1
(en)
|
2021-05-28 |
2024-09-26 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
TW202408589A
(zh)
|
2022-06-30 |
2024-03-01 |
美商舒卓生物製藥公司 |
抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物,及製造及使用抗ror1抗體及抗體結合物之方法
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
WO2024206858A1
(en)
|
2023-03-30 |
2024-10-03 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
WO2024216048A1
(en)
|
2023-04-14 |
2024-10-17 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
US20240352036A1
(en)
|
2023-04-14 |
2024-10-24 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|